Clinical Trials for Angioimmunoblastic T-Cell Lymphoma (AITL)
Angioimmunoblastic T-cell lymphoma (AITL), part of the T-follicular helper (TFH) lymphoma family, is a distinct subtype of peripheral T-cell lymphoma with a unique biology involving the tumor microenvironment. Clinical trials explore epigenetic therapies, novel antibodies, and rational combination regimens.
Live from our database
TrialCompass currently tracks 103 curated clinical trials for AITL
AITL is classified within the broader nodal T-follicular helper (TFH) lymphoma group. TrialCompass includes trials that enroll AITL and other TFH-derived lymphomas.
What types of AITL trials are available?
Trials are grouped by where you are in your treatment journey.
Newly diagnosed
Frontline trials evaluate new combinations and targeted agents added to (or replacing) standard first-line therapy.
Relapsed / refractory
Trials for disease that returned or did not respond, including novel targeted therapies, antibody-drug conjugates, and cellular therapies.
Maintenance / remission
Studies of consolidation or maintenance strategies aimed at keeping the disease from returning after a response.
How to use TrialCompass
- 1Browse AITL trials and use the sidebar filters to narrow by treatment stage, phase, or U.S. state.
- 2Ask the AI Assistant a plain-language question — it searches only trials curated by our hematology specialist.
- 3Generate a letter to bring trials of interest to your oncology team for eligibility review.
Related resources
For completeness, you can also search the U.S. federal registry at ClinicalTrials.gov. TrialCompass curates a physician-selected subset so patients don't have to sift through hundreds of listings.